SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥143.59+CN¥0.70 (+0.49%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.29% below the high.
Loading market information…
HKSE · 2268.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 02:19 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
WuXi XDC Cayman Inc’s quoted price sits in the upper half of its reported 52-week range, 21.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
WuXi XDC Cayman Inc’s next earnings report is currently expected on Mar 29, 2027, with estimated earnings per share of HK$0.93. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow WuXi XDC Cayman Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| HK$0.38+53.66% vs estimate |
| HK$1.67B+8.08% vs estimate |
| Q4 2023 | Mar 25, 2024 | HK$0.12+10.0% vs estimate | HK$1.24B+30.19% vs estimate |
|---|
| Q2 2023 | Dec 31, 2023 | HK$0.09 | HK$1.13B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥143.59+CN¥0.70 (+0.49%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.29% below the high.
₩1,422,000+₩56,000 (+4.1%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.43% below the high.
HK$45.08+HK$0.02 (+0.04%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.28% below the high.
HK$36.70-HK$1.00 (-2.65%)
Genscript Biotech Corporation’s quoted price sits in the upper half of its reported 52-week range, 25.8% below the high.
CN¥133.10-CN¥1.11 (-0.83%)
Asymchem Laboratories (Tianjin) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.45% below the high.
CN¥44.72-CN¥1.06 (-2.32%)
Joinn Laboratories(China)Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 19.68% below the high.
HK$108.20-HK$1.20 (-1.1%)
Duality Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.28% below the high.
HK$19.30-HK$0.11 (-0.57%)
Medtide Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.65% below the high.
